|
|
PROGRAM
TUESDAY, MAY 24, 2005
|
| 09:00 – 11: 30 | MORNING PLENARY SESSION |
Hall A |
|
| 09:00 – 09:15 |
Dr. Aharon Schwartz, Conference Chairperson. Conference Official Opening.
Mr. Ehud Olmert,Vice Prime Minister & Minister of Industry, Trade and Labor. Welcome to conference participants. |
| |
Chairperson: Prof. Itamar Raz, Hadassah University Hospital , Israel |
| 09:15 – 10:00 |
Keynote Speaker: Dr. William J. Rutter, Chairman and CEO Synergenics
Commercializing Bio Science in a Contained Economic Environment. The Synergenics model |
| |
Synergenics Cooperative Biotech Ventures |
| 10:00 – 10:30 |
Prof. Barbara Corkey, Boston University School of Medicine, USA
Gaps In Understanding the pathophysiology of diabetes and obesity
|
| 10:30 – 11:00 |
Prof. Joseph Schlessinger, Yale University School of Medicine, USA
Cell signalling by receptor tyrosine kinases: from the bench to the bedside
|
| 11:00 – 11:30 |
Prof. Lutz Heinemann, Profil Institute for Metabolic Research, Germany
The role of artificial pancreas in the cure of diabetes.
|
| 11:30 – 12:00 |
COFFEE BREAK |
|
| 12:00 – 13:00 |
METABOLIC DISEASES - COMPANY PRESENTATIONS-PARALLEL SESSIONS |
|
| HALL A |
HALL B |
HALL C |
12:00-12:15
D. Avierzer, Protalix Biotherapeutics Ltd
PLANT CELL CULTURES EXPRESSING ENZYME THERAPEUTICS FOR GAUCHER’S DISEASE
|
12:00-12:15
I. Harosh, Obe Therapy
“LEAN GENES” AS TARGETS FOR THE TREATMENT OF OBESITY
|
12:00-12:15
S. Marcus, DeveloGen AG
DEVELOGEN-EUROPEAN LEADER IN METABOLIC DISORDERS
|
12:15-12:30
S. Berliner, Tel Aviv Sourasky Medical Centre
ONLINE CONTROLLING OF MICROINFLAMMATION
|
12:15-12:30
R. Oren , Tel Aviv Sourasky Medical Centre
ROLE OF CYP2D6 POLYMORPHISM IN PREDICTING LIVER FIBROSIS PROGRESSION RATE IN CAUCASIAN PATIENTS WITH CHRONIC HEPATITIS C
|
12:15-12:30
L.D. Ma’ayan, Orsense ltd
THE USE OF NON INVASIVE BLOOD GLUCOSE MONITORING IN DIABETES
|
12:30-12:45
B. Pesach, Glucon
CONTINUOUS, NON-INVASIVE BLOOD GLUCOSE MONITOR BASED ON PHOTOACOUSTIC TECHNOLOGY
|
12:30-12:45
K. Shetty, University of Massachusetts
BIOSYNTHESIS OF DIETARY PHENOLIC ANTIOXIDANTS FOR METABOLIC DISORDERS
|
12:30-12:45
G. Lavin, Transpharma
TRANSDERMAL DELIVERY OF HGH AND INSULIN
|
12:45-13:00
Y. Zicherman, ADM Ltd
THE USE OF A DEVICE THAT APPLIES EXTERNAL KNEADING LIKE FORCE ON THE ABDOMEN FOR THE TREATMENT OF CONSTIPATION
|
12:45-13:00
M. Baru, Omri Laboratories Ltd
PROLONGATION OF PROTEIN HALF-LIFE AND ENHANCEMENT OF BIOLOGICAL ACTIVITY BY FORMULATION WITH PEGYLATED LIPSOMES SHOWS IMPORTANT CLINICAL BENEFITS
|
12:45-13:00
S. Ferber, The Endocrine Institute
CELL-REPLACEMENT THERAPY FOR DIABETES; GENERATING FUNCTIONAL INSULIN PRODUCING TISSUE FROM ADULT HUMAN LIVER CELLS
|
| 13:00 – 14:00 |
LUNCH BREAK |
|
| 14:00 – 16:00 | AFTERNOON PLENARY SESSION |
Hall A |
|
| |
Chairperson: Dr. Rafi Hofstein, Hadasit |
14:00 – 14:30
|
Dr. Eli Ofer - Chief Scientist, Ministry of Industry, Trade & Labor |
| |
The Central Nervous System Session |
| 14:30 – 15:00 |
Prof. Inder Verma, The Salk Institute, USA
Gene Therapy: Two Decades Of Ups And Downs
|
| 15:00 – 15:30 |
Dr. Manfred Windisch, JSW, Austria
Therapy Of Alzheimer’s Disease – Can We Stop Progression?
|
| 15:30 – 16:00 |
Dr. Garnette Sutherland, Foothills Medical Center, Canada
Project neuroArm-Advancing Surgical Robotics |
| 16:00 – 16:30 |
COFFEE BREAK |
|
| 16:30 – 17:30 |
CNS SESSIONS- COMPANY PRESENTATIONS-PARALLEL SESSIONS |
|
| HALL A |
HALL B |
HALL C |
16:30 -16:45
N. Nimrodi, Proneuron Biotechnologies
PRONEURON BIOTECHNOLOGIES
|
16:30 -16:45
I. Gozes, Allon Therapeutics Inc
NAP (AL-108) A NOVEL DRUG CANDITATE FOR THE TREATMENT OF ALZHEIMER’S DISEASE.
|
16:30 -16:45
S. Halachmi, BioLineRx
BL-1020, A NOVEL GABA-TARGETING ANTIPSYCHOTIC WITH IMPROVED THERAPEUTIC PROFILE
|
16:45 -17:00
D. Atlas, Institute of Life Sciences
AD-4, A POTENTIAL DRUG FOR TREATING NEURODEGENERATION
|
16:45 -17:00
Y. Mardor, Sheba Medical Center
ENHANCED EFFICACY AND MR IMAGING OF A NOVEL BRAIN-TUMOR TREATMENT,CONVECTION ENHANCED DRUG DELIVERY (CED)
|
16:45 -17:00
S. Kindler, Pharmos Ltd
PHARMOS CORPORATION PROFILE
|
17:00-17:15
Y. Beck, Brainstorm-cell
BRAINSTORM CELLTHERAPEUTICS-FROM BONE MARROW TO BRAIN CELLS
|
17:00-17:15
J. Aldag , Evotec
EVOTEC-BUILIDING A SUSTAINABLE CNS PORTFOLIO
|
17:00-17:15
A. Hoffman, Intec Pharma Ltd
An “ACCORDION PILL” FOR LEVODOPA CONTROLLED RELEASE IN THE STOMACH
|
17:15-17:30
I. Angel, D-Pharm Ltd.
UPDATE ON DP-B99 A MEMBRANE ACTIVE CHELATOR IN PHASE IIB CLINICAL TRIALS FOR ACUTE STROKE AND DP-VPA A VALPROIC ACID PRODRUG IN PHASE II FOR EPILEPSY
|
17:15-17:30
O. Becker, Predix Pharmaceuticals Ltd
DISCOVERY AND DEVELOPMENT OF PREDIX’S NOVEL ANXIETY AND NOVEL ALZHEIMER’S DRUGS
|
17:15-17:30
V. Teichberg, Weizmann Institute
TREATING ACUTE BRAIN NEURODEGENERATIVE DISEASES WITH BLOOD GLUTAMATE SCAVENGERS
|
|
|
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/bioLogo.gif)
![BIO-TECH ISRAEL 2005: The Israel Biomedical Technologies CONFERENCE AND EXHIBITION [Tel Aviv, Israel, May 24-26, 2005]](images/forTop.gif)
